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Summary Apoptosis can be triggered by cytotoxic agents and radiation currently used in cancer treatment. However, the apoptotic response
appears to vary between cell types (normal or transformed) and between types of malignancy. Thus, irradiation induces apoptosis in normal
human lymphocytes but not in lymphocytes derived from a subset of chronic lymphocytic leukaemia (CLL). Moreover, in this subset,
spontaneous apoptosis is inhibited by irradiation. Why irradiation does not allow the initiation of the apoptotic death pathway could be
explained, at least in part, and in agreement with recent findings on experimental models, by the activation ofthe transcriptional factor NF-KB,
which is able to inhibit apoptotic cell response. Low doses (at which no effect is observed with normal human lymphocytes) of the highly
specific proteasome inhibitor lactacystin are sufficient to trigger apoptosis in these malignant cells. Proteasome inhibition by lactacystin
prevents the nuclear translocation of both p50 and p65 NF-KB subunits and sensitizes these cells to apoptosis by tumour necrosis factor
(TNF)-a treatment. As this subset of CLL is totally resistant to any treatment, proteasome inhibition by lactacystin provides a new therapeutic
approach to be explored, considering the sensitivity of malignant CLL-derived lymphocytes to be quite different from that of normal human
lymphocytes.
Keywords: apoptosis; radiation; lactacystin; resistant chronic lymphocytic leukaemia lymphocyte; TNF-a, NF-KB
One way to improve treatment ofcancer is to activate the molecular
mechanisms involved in programmed cell death (apoptosis).
Alterations of the biochemical mechanisms of cell death, triggered
ornotby drug-target complex, may explain the sensitivity ofcertain
cancer cells to treatment or the resistance of others (Dive and
Hickman, 1991). Thus, ifapoptosis is to be ofinterest as a method-
ological approach in the treatment ofcancer, this implies full under-
standing ofmolecular events associated with this type ofcell death
in various clinical situations. Different agents, including drugs or
irradiation currently used in cancer treatment, can trigger the apop-
totic death process, but only apoptosis induced by activation of the
membrane 'death' receptors Fas or tumour necrosis factor (TNF)-at
is well defined mechanistically (reviewed by Nagata, 1997 and
Golstein, 1997). The molecular pathway of this type of apoptosis,
established using experimental models, can be exploited in human
pathology (Strand et al, 1996; Thome etal, 1997). Thepeculiarity of
activation of the TNF-ax receptor is that signalling may occur
through at least three independent pathways and disclose a number
of opposite cell responses, such as nuclear transcriptional factor
NF-iB activation and cell proliferation or, in contrast, cell death by
apoptosis (Liu et al, 1996). Thus, the life/death balance driven by
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TNF receptor activation must depend upon the subsequent activa-
tion of the cell surviving factor NF-kB (Beg and Baltimore, 1996;
Wang et al, 1996; Van Antwerp et al, 1996).
Ionizing radiation induces apoptotic cell death of human
lymphocytes both in vitro (Delic et al, 1993a) and in vivo (Delic et
al, 1995). The precise molecular mechanisms by which apoptosis
is initiated have yet to be elucidated, but, as we have previously
shown, this type of apoptosis induction involves the activation of
the ubiquitin system (Delic et al, 1993b). In eukaryotic cells,
ubiquitination is a widespread post-translational modification
of proteins fulfilling many normal or pathological functions
(reviewed by Ciechanover, 1994; Wilkinson, 1995). One way by
which the ubiquitin system might control programmed cell death
is through the proteasomal processing or degradation of as yet
unidentified factors. However, the role ofthe proteasomal control
of apoptotic cell death could be two-sided as in sympathetic
neurons (Sadoul et al, 1996) deprived of nerve growth factor
(NGF), orin mouse thymocytes (Grimm et al, 1996) afterdifferent
apoptotic stimuli (including irradiation), the inhibition of protea-
somal activity inhibits apoptosis, whereas in normal human
lymphocytes proteasome inhibition induces and/or sensitizes cells
to apoptosis by irradiation. This suggests that apoptosis-specific
activated pathways depend not only upon the initiation stimulus
but are also specific for a given cell type. Which pathway is acti-
vated, even for the same inducing factor, therefore depends on the
intracellular balance of pre-existing and subsequently activated
factors.
11031104 JDelic etal
In this work, we show that irradiation can result in different cell
responses in normal and malignant human lymphocytes derived
from a subset of chronic lymphocytic leukaemia (CLL) patients
who are clinically resistant to any current therapy. Instead of cell
death initiation by irradiation, we observed an inhibition of spon-
taneous apoptosis in malignant cells. The sensitivity of these cells
for the proteasome inhibitor lactacystin also differed from that of
normal cells. Moreover, lactacystin renders these otherwise resis-
tant cells sensitive to TNF-a-induced apoptosis. The observed
constitutive activation of NF-kB is discussed as a possible mecha-
nism ofresistance to apoptosis induction in these malignant cells.
MATERIALS AND METHODS
Isolation of human lymphocytes and detection of
apoptotic lymphocytes
Peripheral blood lymphocytes were collected from normal and
leukaemic donors (after failure of therapy) with their informed
consent, and cultured as described in detail elsewhere (Delic et al,
1993a; 1995). Cell nuclei were stained with Hoechst 33342
(H 33342, Molecular Probe) at 0.1 ,ug ml-' for 15 min at 370C.
Apoptotic cells were enumerated by fluorescence microscopy as
the proportion of cells disclosing the chromatin morphology
characteristic of apoptosis for a total number of 1000 cells. The
apoptotic cells were counted directly after isolation and after
24 h in culture after irradiation or other treatments.
Irradiation, lactacystin and TNF-a treatments
Lymphocytes were irradiated from 0.2 to 10 Gy in phosphate-
buffered saline (PBS) solution for different times with a 137CS
source (IBL 637, CisBio International) at 2.04 Gy min-'.
Lactacystin (Omura et al, 1991) was prepared as 3 mm stock solu-
tion in dry dimethyl sulphoxide (DMSO) and stored before use at
-20°C. It was added directly to the cell culture immediately after
irradiation at 1-10gM final concentration and maintained in
culture for 24 h. Any apoptotic effect was observed when DMSO-
only cell treatment was used as control. Human recombinant TNF-
a (Sigma-Aldrich) was added simultaneously with lactacystin
(2.5 gM) directly to the cell culture at final concentrations from 10
to 100 pg ml'. The proportion of apoptotic cells as a function of
these different treatments was established after 24 h in culture.
Western blot analysis
Cytoplasmic and nuclear protein extracts from 2.5 x 106 normal
or CLL-derived cells per point were prepared as described
previously (Delic et al, 1993a). After sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), proteins
were transferred to polyvinylidene difluoride (PVDF) membranes
(Immobilion, Millipore) using a BioRad liquid transfer system.
The membranes were incubated overnight at room temperature in
fish gelatine blocking solution (3% in Tris/glycine buffer).
Monoclonal antibodies to NF-icB subunits p50 or p65 (Harlan
Sera-Lab) were used at a dilution of 1:1000, and revealed by a
monoclonal anti-rabbit IgG conjugated to peroxidase. The mono-
clonal antibody to human IkBa (Santa Cruz, CA, USA) was used
at 1:200 dilution, and revealed with an anti-mouse IgG conjugated
to peroxidase. The detection system used was enhanced chemolu-
minescence (ECL, Amersham, UK).
RESULTS AND DISCUSSION
The individual variability in in vitro radiation-induced apoptosis
observed in lymphocytes derived from CLL patients correlated
with their in vivo variable responses to the treatment. Thus, ofthe
25 CLL patients we examined, two were found to be clinically
resistant to any treatment, as were the lymphocytes in vitro to irra-
diation. The 23 otherpatients were clinically sensitive to treatment
and their lymphocytes were sensitive to induction of apoptosis by
irradiation. Unlike normal or sensitive CLL human lymphocytes,
lymphocytes derived from these two CLL patients were unable to
activate the apoptotic death process upon irradiation in vitro.
Resistant CLL lymphocytes, recovered after failure of therapy,
and, after 24 h in culture, included 15% of spontaneously apo-
ptotic cells as identified by fluorescence microscopy ofchromatin
DNA labelled with Hoechst 33342 (Figure IA). Paradoxically,
after irradiation (0.2-10 Gy) and 24 h in culture (time required to
observe chromatin-associated morphological changes character-
istic of apoptosis triggered by irradiation), the percentage of cells
exhibiting apoptotic chromatin morphology decreased to 5%
(Figures IA and 2A), indicating that, in this situation, irradiation
inhibits rather than initiates apoptosis, as it does in normal
lymphocytes (or in lymphocytes derived from other CLL patients
sensitive to irradiation). Similarly, when tested for their sensitivity
to the induction of apoptosis by TNF-a, these cells were found to
be resistant (Figure 2C).
Upon treatment of these resistant cells with lactacystin, a
recently discovered Streptomyces metabolite (Omura et al, 1991)
that specifically inhibits proteasome activity by a covalent alter-
ation ofthe conserved amino-terminal threonine ofthe proteasome
subunit X (Fontennay et al, 1995), cellular sensitivity to apoptosis
induction by TNF-a was restored in a TNF-ax concentration-
dependent manner (Figure 2C). Moreover, the inhibition of the
proteasomal-specific proteolytic activity by lactacystin alone was
sufficient to render these malignant cells prone to apoptosis. As
shown in Figure 2B, the sensitivity to lactacystin-induced apo-
ptosis was quite different between normal human lymphocytes and
resistant CLL lymphocytes, being much greater in the latter case.
In the concentration range from 2.5 to 5 gM, lactacystin very effi-
ciently induced apoptosis in malignant (55% to 85% of apoptotic
cells), but not in normal human lymphocytes (7% to 9%). Even
10 gM lactacystin induced the apoptotic death process in only 20%
of normal cells. At this concentration, all resistant CLL lympho-
cytes (94%) became apoptotic.
In parallel with the observed resistance to apoptosis induction
by irradiation, we observed an increase in the nuclear level of the
p5O subunit of NF-icB (reviewed by Thanos and Maniatis, 1995;
Verma et al, 1995) whereas the constitutively high level of p65
subunit remained unaltered (Figure 3A). As NF-iKB activation is
known to prevent apoptosis induction by different stimuli,
including irradiation (Beg and Baltimore, 1996; Wang et al, 1996;
Van Antwerp et al, 1996), the constitutively high level of p65, in
addition to the nuclear increase in p5O, may explain, at least in
part, why irradiation inhibits rather than induces apoptosis in resis-
tant CLL lymphocytes, and why TNF receptor activation does not
trigger the cell death programme.
As both the degradation of the NF-KcB inhibitor IKBa and the
processing of the p105 precursor of p5O are controlled by the
ubiquitin-proteasome proteolytic pathway (reviewed by Verma et
al, 1995), inhibition of the proteasome should further inhibit the
activation of NF-KcB and subsequently favour the initiation of
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Figure 1 Changes in apoptotic resistant CLL-lymphocyte population as a result of irradiation, lactacystin or TNF-a treatments. Apoptotic nuclei of CLL-derived
lymphocytes (from one resistant CLL donor) visualized by fluorescence microscopy after Hoechst 33342 chromatin DNA labelling. Apoptosis-characteristic
fluorescence (bright) patterns can be clearly distinguished from that of non-apoptotic cells (darkfluorescence). Cells were observed after 24 h in cell culture
(A) without any treatment, (B) after 10 Gy irradiation, (C) treatment with 2.5gM lactacystin, and (D) simultaneous treatment with 0.1 ng ml-1 of TNF-a and 2.5gM
lactacystin. The initial number of the apoptotic cells (brightly labelled in A) decreased after irradiation at 10 Gy (B). Proteasome inhibition sensitized resistant
CLL lymphocytes to apoptosis induced by TNF-a as the proportion of apoptotic cells observed in lactacystin-treated cells (C) increased after combined
lactacystinfTNF-a cell treatment (D)
apoptosis. This effectively occurred in CLL cells treated with
lactacystin (Figure 3B), in which a decreased nuclear level of the
p5O subunit and, more dramatically, of the p65 subunit was
observed. The decrease in p65 occurred concurrently with an
increase in the cytoplasmic level ofIKBa (Figure 3B), the specific
inhibitor ofp65 (Haskill et al, 1991).
Thus, stimulation of the TNF receptor by exogenous TNF-oa
could initiate the apoptotic cell death pathway when the constitu-
tive NF-KB activation was reverted by lactacystin (Figure 2C).
Surprisingly, lactacystin-treated resistant CLL lymphocytes were
not sensitized to irradiation-induced apoptosis (at least not at the
lactacystin concentrations that potentiate radiation-induced
apoptosis in normal lymphocytes). When irradiated at 10 Gy and
treated with 1 gM lactacystin, resistant CLL lymphocytes were
more resistant to apoptosis than cells treated with lactacystin
alone. In contrast, radiation-induced apoptosis was potentiated in
normal human lymphocytes at the same lactacystin concentrations.
Higher doses of lactacystin were required to induce significant
apoptosis in resistant CLL lymphocytes than in normal lympho-
cytes after irradiation (Figure 2B). This was observed in spite of
the absence of an increase in nuclear p5O level at different times
after irradiation and lactacystin treatment. However, the p5O level
was higher in the nuclei ofcells treated with lactacystin and irradi-
ation than in the cells treated with lactacystin only (Figure 3B).
This was even more conspicuous for the remaining high nuclear
p65 and the decreased cytoplasmic, most probably phosphoryl-
ated, form ofIiKBa in cells treated with lactacystin and irradiation.
This observation is consistent with the fact that lactacystin renders
resistant CLL lymphocytes sensitive to apoptosis induced by TNF-
x but notby irradiation as the cytoplasmic IKBBa, which is required
for the post-induction repression of NF-KB (Beg et al, 1995), was
not increased upon irradiation. It might also indicate that, in addi-
tion to the modulation of different components of the NF-KB/IKB
family, irradiation involves other activated transduction pathways
necessary for completing apoptosis in these CLL cells, which are
altered compared with normal human lymphocytes and which are
not requested for the TNF receptor-driven NF-KB life-death
balance control. This is further supported by the fact that in normal
cells TNF-a has no effect on apoptosis after inhibition of protea-
some by lactacystin (not shown), suggesting that in normal, unlike
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Figure 2 Proportion of apoptotic cells 24 h after irradiation and/or treatment
with lactacystin and/or TNF-a: radiation dose- and drug concentration-
dependent effects. Normal lymphocytes, 0; resistant CLL lymphocytes, A.
(A) Comparison of radiosensitivity to apoptosis of lymphocytes treated by
irradiation (0.2-10 Gy) only. (B) Cells treated with lactacystin (1-10gM),
without ( ) or with (- - -) additional irradiation (10 Gy). (C) CLL-
derived cells treated with TNF-a alone at the indicated concentrations
(-
- -), and with TNF-a plus lactacystin at 2.5 gM (-). Note the inhibition of
spontaneous apoptosis by 10 Gy irradiation in CLL-derived lymphocytes as
well as the induction of apoptosis or sensitization to TNF-a treatment by
lactacystin of these otherwise resistant cells
in malignant, cells apoptosis induction by radiation is not elicited
by physiological NF-iB activity.
Thus, the essential difference between normal and resistant
CLL lymphocytes is their sensitivity to lactacystin. Even if it is
a non-discriminatory inhibitor of ubiquitin-dependent protein
processing, lactacystin can be effective, in a discriminatory
Figure 3 Inhibition of constitutive nuclear localization of NF-KB by
lactacystin. Westem blot analysis showing the altered NF-IcB/IkBa levels
upon irradiation (10 Gy) and/or lactacystin (2.5gM) treatment of CLL-derived
human lymphocytes. (A) The nuclear NF-KB subunit p50 level progressively
increased and remained high in CLL-lymphocytes, even 24 h after irradiation,
whereas in normal cells its level remained unaltered and had clearly
diminished at 24 h post-irradiation. The nuclear p65 level remained unaltered
but constitutively high in CLL-lymphocytes compared with normal cells after
irradiation. (B) The level of NF-KB subunits decreased in CLL-derived cells
treated with 2.5gM lactacystin alone but not in cells treated simultaneously
with lactacystin and irradiation, in which p50 is higher than in cells treated
with lactacystin only. This is even more conspicuous for the level of the p65
subunit, which disappeared upon treatment with lactacystin alone. Correlated
with this is the increase in the cytoplasmic lIcBa level in lactacystin-treated
cells but not in cells treated with lactacystin plus irradiation. Note that the
decreasing nuclear level of the p65 subunit correlates with the increasing
cytoplasmic level of licBa at different time points of lactacystin treatment.
Point 0 in A and B correspond to untreated cells
manner, in specific pathological situations as the cell response is
concentration dependent. The apoptotic responses of normal and
cancer cells, which differ for identical lactacystin concentrations,
correlated with the constitutively high expression level ofthe tran-
scriptional factor NF-KB, which is able to prevent apoptosis, in
malignant but not in normal cells. NF-KcB activity in these malig-
nant cells can be blocked through proteasomal inhibition by lacta-
cystin, which can be sufficient for apoptosis triggering and/or to
sensitize these cells to apoptosis by TNF-ax receptor activation.
The observation that these resistant CLL cells became apoptotic
and/or apoptosis-prone upon proteasome inhibition by lactacystin
treatment, in a dose-dependent manner that is quite different from
that of normal lymphocytes, suggests that a new therapeutic
approach to this completely resistant group ofCLL patients can be
envisaged.
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